Cystinosis is an autosomal recessive metabolic disease that belongs to the family of lysosomal storage disorders (LSDs). The defective gene is CTNS encoding the lysosomal cystine transporter, cystinosin. Cystine accumulates in all tissues and leads to organ damage including endstage renal disease. Using the Ctns −/− murine model for cystinosis, we tested the use of hematopoietic stem and progenitor cells (HSPC) genetically modified to express a functional CTNS transgene using a self-inactivatinglentiviral vector (SIN-LV). We showed that transduced cells were capable of decreasing cystine content in all tissues and improved kidney function. Transduced HSPC retained their differentiative capabilities, populating all tissue compartments examined and allowing long-term expression of the transgene. Direct correlation between the levels of lentiviral DNA present in the peripheral blood and the levels present in tissues were demonstrated, which could be useful to follow future patients. Using a new model of cystinosis, the DsRed Ctns −/− mice, and a LV driving the expression of the fusion protein cystinosinenhanced green fluorescent protein (eGFP), we showed that cystinosin was transferred from CTNS-expressing cells to Ctns-deficient adjacent cells in vitro and in vivo. This transfer led to cystine decreases in Ctns-deficient cells in vitro. These data suggest that the mechanism of cross-correction is possible in cystinosis.
IntroductIon
Numbers of reports have established a proof-of-principle for allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation in several lysosomal storage disorders (LSDs). 1 However, a suitable hematopoietic donor is not always found and the risk of morbidity and mortality associated with allogeneic transplantation is significant. The major complication is graft-versushost disease (GVHD). 2, 3 In recent studies, acute GVHD grade II-IV occurred in 20-32% of patients and chronic GVHD in 16-59%, both significantly impacting survival of the recipients. [4] [5] [6] Moreover, high risks of infection related to the myeloablative regimen and immunosuppressive medications account for 16-19% of deaths. 7, 8 Thus, even though the risk/benefit ratio of allogeneic hematopoietic stem cell (HSC) transplantation still favors selected LSDs, it remains an uncertain therapeutic choice for others. In contrast, autologous HSPC transplantation, if successful, would greatly expand the opportunities to apply this strategy in any LSD because it avoids the risks of GVHD and may be done with a reduced intensity myeloablative regimen.
Cystinosis is an LSD that could benefit from autologous genemodified HSPC transplantation. Since the introduction and regular use of the drug cysteamine, many patients may live to adulthood but with significant medical problems and the mean age of death is around 28 years old. 9 Cystinosis is characterized by lysosomal accumulation of cystine, which leads to the formation of cystine crystals and multiple organ dysfunction and progressive degeneration. The gene underlying cystinosis, CTNS, encodes a seven transmembrane domain protein, cystinosin, a lysosomal cystine transporter. The second step is described in this article by establishing an autologous HSPC transplantation protocol for this disease using a self-inactivating-lentivirus vector (SIN-LV) containing a functional human CTNS cDNA. SIN-LVs have shown tremendous benefit as a vehicle for gene delivery as they efficiently transduce many different cell types including stem cells [19] [20] [21] [22] and present many safety features. [23] [24] [25] [26] Numerous studies have shown the long-term efficacy of lentiviral-transduced hematopoietic cells in mouse models of other LSD. [27] [28] [29] [30] Recently, a proof-of-concept for the potential efficacy of SIN-LVs was observed in a clinical trial involving ex vivo modified HSC for a peroxisomal storage disorder, X-linked adrenoleukodystrophy. 31 We now report studies on the use of a LV to correct the gene defect in the murine model of cystinosis that will support the first gene and cell therapy clinical trial. Using this strategy to deliver a fusion protein cystinosinenhanced green fluorescent protein (eGFP) and a new mouse model for cystinosis constitutively expressing a DsRed reporter gene, we also provide new insights into the mechanisms of the long-term therapeutic effects of transplanted HSPC expressing a functional CTNS gene.
results lentiviral HsPc transduction as an efficient and stable vehicle for long-term transgene expression within tissues in the cystinosis mouse model
The human CTNS, eGFP, and luciferase (LUC) cDNA were subcloned in the SIN-LV pCCL-EFS-X-WPRE (pCCL). The constructs pCCL-eGFP and pCCL-LUC were used to optimize transduction of murine Sca1 + HSPC and to monitor the efficiency and stability of transgene expression over time in Ctns −/− mice. Freshly isolated wild-type Sca1-enriched cells were transduced with pCCL-eGFP and pCCL-LUC ex vivo with LV particles added at multiplicity of infection 5, 10 or 20. Optimal transduction efficiency was obtained with an multiplicity of infection of 10 (data not shown).
Ex vivo transduction efficiency and transgene expression stability were measured in vivo either in peripheral blood by flow cytometry to quantify eGFP + cells or using the IVIS imaging system to quantify luciferase expression in live mice. High levels of eGFP + cells in the blood of eight transplanted mice were detected, ranging from 26.7 to 93.5% at 4 months post-transplant. Levels were stable up to 9 months post-transplant, which represents the last time point measured for this study (Figure 1a) . The mean number of eGFP + cells in the blood of the mice was 70.6 ± 22.0% and the mean contribution for each lineage: 9.6 ± 2.6% T-lymphocytes, 37.0 ± 19.7% B-lymphocytes, and 13.6 ± 7.2% monocytes (Figure 1b) . The remaining eGFP + cells were granulocytes. High levels of pCCL-eGFP-transduced bone marrow-derived cells were observed in all the tissues tested including the kidney, liver, spleen, and brain of Ctns −/− mice as previously observed for wild-type eGFP HSPC 17, 18 (Figure 2 ). These cells strongly expressed eGFP as determined by direct fluorescence and by immunofluorescence staining using an anti-GFP antibody (Figure 2b ). In addition, we showed that most of the differentiated eGFP-expressing bone marrow-derived cells are Kupffer cells in the liver, microglial cells in the brain, and inflammatory dendritic cells in the kidney, colocalizing with an anti-F4/80 antibody (Figure 2c-e) and as shown previously. 17, 18 No eGFP-positive cells and no anti-GFP staining were seen in non-transplanted controls (Figure 2a) . These data showed that ex vivo transduction and manipulation of the HSPC did not affect their differentiative capacity. Finally, high levels of luciferase expression were also observed in eight Ctns −/− mice transplanted with pCCL-LUC-transduced HSPC in tissues up to 12 months post-transplantation, the last time point considered for this study (Figure 1c) . These data showed that ex vivo transduced HSPC still efficiently engrafted in tissues in Ctns −/− mice and that the transgene was highly expressed for up to a year.
long-term in vivo correction
We are working with the human CTNS cDNA and using a vector backbone currently used in clinical trials 31 in these mouse model studies to establish the preclinical proof-of-concept for a human trial. The construct pCCL-CTNS was first verified in vitro. Gene transfer of CTNS cDNA into murine Ctns −/− fibroblasts led to high expression of CTNS transcripts and a significant decrease of cystine compared with pCCL-eGFP-transduced or non-transduced Ctns −/− fibroblast controls (Figure 3a) . Sca1 + HSPC isolated from Ctns −/− mice were transduced ex vivo with pCCL-CTNS using an multiplicity of infection of 10 and transplanted into 1-4 months old Ctns −/− mice. The rationale for this choice was to be a first proof-of-concept that this strategy of gene-modified HSPC transplantation could work in young patients with cystinosis before significant disease progression. Cystine contents of brain, eye, heart, kidney, liver, muscle, and spleen were analyzed after 4 (group 1; n = 8) and 8 (group 2; n = 12) months post-transplantation, corresponding to 6-8 months and 9-11 months old mice, respectively. As controls, we used age-matched non-treated Ctns −/− mice (n = 7 and n = 12) or transplanted with wild-type HSPC (n = 4 and n = 4). Decreases in cystine content were statistically significant in all the tissues tested of mice treated with pCCL-CTNS-transduced HSPC compared with Ctns −/− controls except the kidney at 4 months post-transplant and the kidney and eye at 8 months (Figure 3b) . The levels of decrease observed in Ctns −/− mice treated with wild-type syngeneic HSPC were significantly better in most tissues compared to the mice treated with pCCL-CTNS-transduced HSPC except in brain and kidney at 8 months post-transplantation (Figure 3b) . As previously shown, 17 no benefit was observed in Ctns −/− mice transplanted with Ctns −/− HSPC being equivalent to the non-treated mice (P > 0.05 for all tissues; data not shown). We also tested the impact of Ctns −/− HSPC transduced with control vector, pCCL-eGFP, on tissue cystine levels to exclude the possibility that the presence of any transgene results in cystine decreases. No decrease in cystine levels in any tissue was observed in Ctns −/− mice transplanted with pCCL-eGFP-transduced Ctns −/− HSPC (n = 2) compared with non-treated Ctns −/− mice (n = 2) at 11 months post-transplantation, consistent with the conclusion that cystine decreases obtained in pCCL-CTNStreated mice are specifically due to the presence of the CTNS gene (data not shown). Curiously, the kidney was the only tissue in which no significant cystine decrease could be consistently obtained with either wild-type or lentiviral-modified HSPC. Comparison of tissue cystine content of non-treated Ctns −/− male and female mice revealed that cystine levels were significantly higher in female kidneys than in males (194.91 ± 114.73 in females versus 70.02 ± 23.10 in males; P < 0.001). The other tissues did not present such a difference (data not shown). We tested several age groups. After 13 months of age, the difference between males and females in kidney cystine content was no longer observed (data not shown). These new data highlight the fact that males and females have to be analyzed separately for these kidney studies. Thus, we compared kidney cystine content in male Ctns −/− mice treated with pCCL-CTNS (n = 8) and non-treated controls (n = 9) at 8 months post-transplantation. A significant decrease of cystine content in kidney was observed in the treated males (Figure 3c) . Moreover, quantification of cystine crystals in the kidney sections revealed a significant decrease of crystals in the pCCL-CTNS-treated males compared with nontreated controls (Figure 4) .
Renal function was assessed by measuring creatinine, urea, and phosphate levels in the serum, and creatinine clearance in 24-hour urine collections in the males at 8 months post-transplant and compared with age-matched wild-type males (n = 6). In nontreated Ctns −/− mice, the creatinine clearance decreased and all other parameters measured increased compared with wild-type mice ( Table 1 ). In the pCCL-CTNS-treated Ctns −/− mice, serum creatinine, urine phosphate, and urine volume were significantly decreased compared with non-treated controls, showing a beneficial effect of the genetically modified HSPC on kidney function in Ctns −/− mice ( Table 1) .
correlations between transduction efficiencies in blood and transduced bone marrow-derived cells present in tissues Reverse transcription-quantitative PCR (qPCR) of total RNA purified from whole blood of pCCL-CTNS-transplanted Ctns −/− mice with CTNS-specific primers showed that CTNS transcripts were expressed in circulating blood cells; the mean value was 332 ± 238 expressed as 18S-normalized fold change (CTNS expression level was 199 ± 149 in normal human blood; n = 3). We then performed qPCR on genomic DNA from the tissues and blood of 18 pCCL-CTNS-transplanted Ctns −/− mice with LV-specific primers. No lentiviral DNA was detected in the control Ctns −/− mice. The pCCL levels measured in the transplanted Ctns −/− mice were as follows and correspond to the copy of viral vector per cell present in the corresponding compartment: blood, 1.573 ± 1.868; brain, 0.001 ± 0.0005; kidney, 0.0363 ± 0.0284; liver, 0.066 ± 0.047; spleen, 0.273 ± 0.161. In order to determine whether LV quantity could be easily predicted in tissues, we performed linear regression analyses between pCCL levels in the different tissues as a function of blood pCCL levels. We found significant correlations for all the tissues tested except the kidney, showing that the higher the level of LV DNA detected in the blood, the higher the levels are in the tissues: brain, transplanted with pCCL-CTNS (n = 20) and did not reveal any abnormalities.
Chromosomal insertion sites were analyzed by ligation-mediated PCR in the spleen and blood of 13 pCCL-CTNS-transplanted mice. Figure 5 reveals the finding of two distinct adjacent amplicons that could suggest the presence of a clonal pattern. However, sequencing of these two bands revealed that both amplicons were located in noncoding genomic DNA in chromosome 10 and 16, implying that no insertional mutagenesis occurred.
cross-correction may occur in cystinosis
To study a potential transfer of the functional cystinosin from bone marrow-derived cells to host adjacent cells, we generated a new Ctns −/− mouse model, the DsRed Ctns −/− mice, that constitutively express the DsRed reporter gene. This new mouse model was used to isolate HSPC that were DsRed Ctns −/− . We also generated a pCCL LV expressing a cystinosin-eGFP fusion protein. The functionality of the fusion protein was verified in vitro by transducing Ctns −/− fibroblasts. Cystinosin-eGFP fusion protein appeared in intracellular vesicles that colocalized with a lysosome-staining dye, LysoTracker, demonstrating that cystinosin is targeted correctly to the lysosomes (Figure 6a) . Western blot analysis with an anti-GFP antibody revealed several bands between 70 and 85 kDa in the transduced fibroblasts that correspond to the cystinosin-eGFP at different stages of glycosylation 10 (Figure 6b) . Finally, cystine content was significantly decreased in the pCCL-CTNSeGFP-transduced Ctns −/− fibroblasts (n = 6) compared with non-transduced controls (n = 6) proving that the protein was functional (Figure 6c) .
To investigate a potential cross-correction in vitro, we cocultured DsRed Ctns −/− fibroblasts and pCCL-CTNSeGFP-transduced Ctns −/− fibroblasts for 2 weeks. Microscopy analysis revealed the Figure 4 cystine crystal quantification in kidney sections from male Ctns −/− mice. Kidney sections stained with methylene blue in ethanol were used to observe cystine crystals. Low magnification pictures were analyzed using ImageJ software. Abundant cystine crystals were observed in kidney sections from non-treated Ctns −/− males (n = 9) in contrast to pCCL-CTNS-treated males (n = 8). Wild-type mice (n = 4) were used as negative control for our method of cystine crystal detection using ImageJ. Error bars are defined as mean ± SD, *P < 0.05. presence of green vesicles in the DsRed cells, suggesting the transfer of the cystinosin from the CTNS-expressing cells to adjacent cells (Figure 6d) . Cystine measurements of the DsRed-expressing cells after sorting to exclude the pCCL-CTNSeGFP-fibroblasts showed a significant cystine decrease in the cocultured DsRed Ctns −/− fibroblasts compared with the sorted DsRed Ctns −/− cells cultured alone (Figure 6e) . These data showed that a transfer of functional cystinosin occurs in vitro from CTNS-expressing cells to adjacent cells.
To study potential cross-correction in vivo, we transplanted our original Ctns −/− mouse model with DsRed Ctns −/− HSPC transduced with pCCL-CTNSeGFP (CTNSeGFP-DsRed-HSPC mice; n = 5). We used non-transplanted (n = 2) and DsRed Ctns −/− HSPC-transplanted (DsRed-HSPC mice; n = 2) Ctns −/− mice as controls. DsRed-expressing donor cell blood engraftment was 96.4 ± 1.1% in DsRed-HSPC mice and 81.3 ± 9.1% in the CTNSeGFP-DsRed-HSPC mice. In both groups of mice, bone marrow-derived DsRed-expressing cells were observed abundantly in tissues by confocal microscopy as expected; we focused our studies on the liver (Figure 7) . However, only in CTNSeGFPDsRed-HSPC mice could we observe eGFP-positive intracellular vesicles in some DsRed-expressing bone marrow-derived cells within tissues (Figure 7) . The eGFP-positive intracellular vesicles colocalized with the lysosome-specific antibody Lamp-2, showing that cystinosin was targeted to the lysosomes (Figure 7b) . Some of the eGFP-positive intracellular vesicles in CTNS-expressing DsRed cells were large structures (Figure 7a,b) . Remarkably, we also observed non-color host tissue cells containing discrete green vesicles consistent with the transfer of cystinosin-eGFP fusion protein from the transduced bone marrow-derived DsRed cells (Figure 7a; arrows) . These vesicles also colocalized with antiLamp 2 antibodies (Figure 7b ; arrows) demonstrating that the cystinosin-eGFP fusion protein was located in the correct intracellular compartment. No eGFP-positive intracellular vesicles were observed in the control DsRed-HSPC mice (Figure 7c,d) .
dIscussIon
We previously showed the potential of using wild-type HSPC transplantation for cystinosis, a multisystemic LSD due to a dysfunctional lysosomal transmembrane protein. 17 These results indicated that bone marrow cell transplantation could be a long-term systemic treatment for this disease, but also for other multisystemic diseases due to dysfunctional intracellular proteins. However, the risks related to allogeneic HSC transplantation limit its implementation especially when a treatment delaying the progression of the disease exists as in the case of cystinosis. Autologous transplantation of genetically modified HSPC would minimize the risks and thus would generalize the use of such therapy for genetic diseases. However, gene therapy also carries some risks as demonstrated by several cases of leukemia in a clinical trial using murine leukemia virus-transduced human HSC for X-linked severe combined immunodeficiency children. 32 In contrast to murine leukemia virus vectors, SIN-LV may be safer virus vectors for gene therapy. 23, 25 We showed that ex vivo lentiviral-transduced Ctns −/− HSPC expressing a functional CTNS gene led to long-term cystine decreases in all tissues. In contrast, a previous study using a human adenovirus vector containing CTNS administered via tail vein in the Ctns −/− mice showed only a short-term impact on cystine decrease in the liver. 33 The variation of results in cystine levels we obtained probably depends on the transduction efficiency of the transplanted HSPC and variations in engraftment levels as previously described. 18 We measured the transduction efficiency in the peripheral blood and showed that this was significantly correlated to the quantity of corrected cells present in tissues. We propose that this strategy may become a noninvasive method to monitor future cystinotic patients after transplantation. Moreover, we showed previously that the level of Ctns-expressing donor-derived blood cell engraftment was a determinant factor for kidney preservation in the Ctns −/− mice after syngeneic HSPC transplantation. 18 Curiously, the kidney was the only tissue in which no significant cystine decrease could be obtained with either wild-type or lentiviral-modified HSPC. In the process of understanding the nature of this discrepancy, we discovered that a significant difference exists in kidney cystine content between male and female Ctns −/− mice. Is that true in humans? Why is there a difference in cystine content between males and females in the kidney and not the other organs? These questions will need further investigation and highlight the complexity of kidney pathogenesis in cystinosis. In this study, when we analyzed the males separately at 8 months post-transplantation, cystine content and cystine crystals were significantly decreased in the kidney of pCCL-CTNS-treated mice compared with non-treated controls and the renal function was improved. These data show the beneficial therapeutic effect of the transplantation of genetically modified Ctns-deficient HSPC using a LV to introduce a functional CTNS gene in the Ctns −/− mice. We showed that lentivirus-transduced HSPC retained the same differentiative capacity after transplantation as wild-type HSPC, capable of migrating abundantly to all tissues in Ctns −/− mice and engraft as shown previously. 17 This is an important point as the ex vivo cytokine activation of HSPC to facilitate transduction may alter the lineage commitment pathways of progenitor cells. 34, 35 We observed differentiation into dendritic cells in the kidney or resident macrophage-derived cells within tissues such as Kupffer cells in the liver and microglial cells in the brain. In most tissues, the impact of transplanting wild-type HSPC was greater than pCCL-CTNS-transduced HSPC. These data suggest that the quantity of progenitors expressing CTNS matters more than the overexpression of CTNS per cell. We suspect that resident macrophage-derived cells have a major role in the pathogenesis of cystinosis. Their replacement by bone marrow-derived cells expressing CTNS could explain the majority of cystine depletion by the phagocytosis of cystine-overloaded cells. Indeed, Kupffer cells contain 75% of the total cystine content in the liver whereas they only represent ≤10% of the total cells in the liver. 33 However, we showed previously a short-term improvement after mesenchymal stem cell transplantation in Ctns −/− mice including tissue cystine decrease and renal function amelioration, suggesting a paracrine effect of the mesenchymal stem cells. 17 Also, in the brain, lentiviral-transduced cells had a higher and more consistent impact on cystine decrease than the wildtype HSPC at 8 months post-transplantation. This phenomenon has been previously described in the case of HSC gene therapy for the treatment of the central nervous system anomalies in the murine model of metachromatic leukodystrophy. 27 The hypothesis that was proposed was overexpression of the aryl-sulfatase A gene in bone marrow-derived microglial cells delivered functional enzymes to the adjacent cells in the brain. Thus, all these data suggest that a transfer of the cystinosin protein to adjacent cells could occur. Cross-correction has been well demonstrated in the case of secreted enzymes in several LSDs such as Hurler syndrome. 36 In this case and in the case of other LSDs due to a lysosomal enzyme deficiency, the uptake of the enzymes from the extracellular milieu by neighboring cells is performed via the mannose-6-phosphate receptor that subsequently mediates endocytosis and lysosomal targeting. [37] [38] [39] In the case of cystinosis, the protein involved is a seven transmembrane lysosomal protein. Direct secretion of the cystinosin is not possible, but cross-correction could occur via transfer of vesicles containing cystinosin.
To test this hypothesis, we generated a new cystinosis mouse model that ubiquitously expressed the DsRed reporter gene. DsRed Ctns −/− HSPC were transduced with a LV containing the CTNS-eGFP fusion cDNA and transplanted in our regular Ctns −/− mice. Cystinosin-eGFP was observed in the lysosomes of DsRedexpressing bone marrow-derived cells within the tissues. Some of the Lamp-2-positive eGFP-positive vesicles looked like large structures, probably due to the clustering and/or fusion of lysosomes as a consequence of CTNS overexpression as previously described. 10 The long-term consequence of this phenomenon is unknown. Remarkably, we also observed host cells containing discrete eGFPpositive intracellular vesicles. This showed that, even if cystinosin is a lysosomal transmembrane protein, a transfer to adjacent cells is possible. In vitro, we showed that cystinosin transfer led to cystine decrease in Ctns-deficient cells. The transfer could occur via CTNS genetic material-containing microvesicles or exosomes, both released from the endosomal compartment. 40, 41 We showed that cystinosin is present in lysosomal vesicles after transfer but we do not know whether CTNS mRNA or cystinosin protein were transferred. Most of the microvesicles/exosomes described contain microRNA or mRNA 41 but proteins have also been found. 42 Further studies will be necessary to answer this question. The second question will be to determine the route of transfer. Are membrane vesicles shed from cells to mediate transfer of CTNS genetic material to adjacent cells? Alternatively, are intercellular plasma membrane connections such as nanotubes involved? 43 Bone marrow stem cells have previously been shown to have a paracrine effect via microvesicle exchange for tissue repair. 44, 45 Nanotubes between macrophages have been described and were shown to allow the trafficking of mitochondria and intracellular vesicles such as lysosomes. 46 In our case, direct transfer of cystinosin-containing lysosomes could be possible. We believe that bone marrow-derived macrophages within tissues expressing a functional CTNS gene could have a double therapeutic action by phagocytosing cystine-overloaded cells and by providing a functional protein to adjacent cells.
This work represents the first step towards a clinical trial for cystinosis using autologous HSPC genetically modified ex vivo to express a functional CTNS transgene using a SIN-LV. We were also able to provide some insights into the mechanism of the long-term therapeutic effect of transplanted HSPC expressing a functional CTNS and showed the possibility of cross-correction in the case of cystinosis treated by transplantation of gene-modified HSPC. This is a proof-of-concept for many hereditary genetic diseases for which curative therapy requires the addition of the gene to many cells, typically in multiple tissue compartments, and where the protein involved is an intracellular transmembrane protein.
MaterIals and MetHods
Mice. C57BL/6 Ctns −/− mice were provided by Dr Antignac (Inserm U983, Paris, France). B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J (Jackson Laboratory, Bar Harbor, ME) mice were cross-bred with the C57BL/6 Ctns −/− mice to produce the transgenic DsRed Ctns −/− mice constitutively expressing the DsRed fluorescent protein under the control of the chicken β-actin promoter coupled with the cytomegalovirus immediate early enhancer. All strains were bred continuously at The Scripps Research Institute (TSRI) such as wild-type C57BL/6 mice. All protocols were approved by the AAALACAccredited Institutional Animal Care and Use Committee of TSRI.
Generation of CTNS-, eGFP-, and LUC-LVs. The SIN-LV, pCCL-EFS-X-WPRE (pCCL) was used for gene transfer. The vector backbone is based on the pCCL LVs 47 and contains the intron-less human elongation factor 1α promoter (242 bp) to drive the transgene expression. 48 The eGFP, LUC, and the human CTNS cDNA as well as the fusion CTNS-eGFP cDNA were inserted into pCCL at the BamHI and SalI restriction sites; they were named pCCL-eGFP, pCCL-LUC, pCCL-CTNS, and pCCL-CTNSeGFP, respectively. CTNS was amplified from the vector pcDNA-CTNS kindly provided by Dr Antignac.
Production of LV and titers. Infectious lentiviral particles were produced using the transient tri-transfection procedure in human embryonic kidney 293T cells. Packaging plasmids (pMDLg/pRRE, pHCMV-G, and pRSVRev) along with the expression constructs, were used resulting in the assembly of vesicular stomatitis virus-G glycoprotein pseudotyped viral particles. Vector particles were collected in 25 ml of Stemspan medium (StemCell Technologies, Vancouver, British Columbia, Canada) and concentrated 100 times by ultracentrifugation at 25,000 rpm for 2 hours at 4 °C. Titers of concentrated virus were measured by infection of 293T cells after serial dilutions of the virus preparations and determined by flow cytometry for pCCL-eGFP and IVIS imaging system for pCCL-LUC. Titers for pCCL-CTNS viral particles were measured by infection of Ctns −/− fibroblast cells and determined by qPCR on genomic DNA as described below. Viral titers of concentrated supernatant ranged from 6 × 10 8 to 8 × 10 8 transducing units/ml depending on the vector. Replication competent lentivirus was absent in the vector preparation and the blood of the transplanted mice using a vector rescue assay.
HSPC enrichment, transduction, and transplantation. Bone marrow cells were flushed from the femur and tibia of 6-8 weeks old Ctns −/− or wild-type mice. HSPC were isolated by immunomagnetic separation using anti-Sca1 antibody conjugated to magnetic beads (Miltenyi Biotec, Auburn, CA). Sca1 + HSPC were resuspended in Stemspan supplemented with murine stem cell factor, thrombopoietin, and murine FMS-like tyrosine kinase 3-ligand (mFlt3L) at a concentration of 100 ng/ml, and murine interleukin-6 (mIL-6; PeproTech, Rocky Hill, NJ) at 20 ng/ml. The cells were plated at a density of 2 × 10 6 cells in 0.5 ml of media per well in a 24-well plate. The plate was pretreated with 300 μl of RetroNectin (Takara Bio USA, Madison, WI) at 20 μg/ml. Sca1 + HSPC were transduced with lentiviral particles in the presence of polybrene (4 μg/ml) and incubated for 16 hours at 37 °C, 5% CO 2 . Cells from each well were collected and washed twice in phosphate-buffered saline and then resuspended in 200 µl of phosphatebuffered saline. Tail vein injection of 100 µl containing ~1 × 10 6 cells was performed in each Ctns −/− mice lethally irradiated (8Gy) on the previous day.
Lineage reconstitution determination with transduced HSPC. Fresh blood of pCCL-eGFP-HSPC-transplanted mice was treated with red blood cell lysis buffer (eBioscience, San Diego, CA) and analyzed by flow cytometry to quantify eGFP + cells and hematopoietic lineage-specific cell types after subset antibody staining. T cells were stained with phycoerythrin-conjugated anti-CD3ε, B cells with phycoerythrin-conjugated anti-CD19, and macrophages with phycoerythrin-conjugated anti-CD11b (BD Biosciences, San Jose, CA). Appropriate isotype controls were used for each.
Immunofluorescence analysis. Tissues were fixed in formaldehyde 5%, equilibrated in sucrose 20% overnight and frozen in Tissue-Tek Optimal Cutting Temperature buffer at −80 °C (Sakura Finetek U.S.A, Torrance, CA); 10 μm sections were cut and stained with DAPI, Bodipy-Phalloidin or Alexa Fluor 647-Phalloidin (1:500 dilutions for 30 minutes; Molecular Probes, Eugene, OR). Tissues were also stained with a rabbit anti-GFP antibody (1:200 dilution; Abcam, Cambridge, MA) and a rabbit anti-LAMP2 antibody (1:100 dilution; Abcam), followed by a donkey anti-rabbit conjugated with Cy5 (dilution 1:200; Jackson ImmunoResearch Laboratories, West Grove, PA). Tissues were also stained with a directly labeled Alexa Fluor 647-rat antimouse F4/80 antibody (1:25 dilution; AbD Serotec, Raleigh, NC). Culture cells were stained with a LysoTracker-Red DND-99 (Invitrogen, Carlsbad, CA) at a concentration of 75 nmol/l for 1 hour before fixation. Images were acquired using a Zeiss LSM 710 laser scanning confocal microscope attached to a Zeiss Observer Z 1 (BioRad-Carl Zeiss, Thornwood, NY). All images were 8-bit optical image slices (0.5 μm interval step slices) acquired using LaserSharp 2000 software (BioRad, Hercules, CA). Images were then analyzed with IMARIS 4.2 imaging software (Bitplane Scientific Solutions, Saint Paul, MN) to generate 3-D reconstruction series of optical slices (Z-stacks).
Live animal LUC imaging. Mice transplanted with pCCL-LUC-transduced HSPC were analyzed using the IVIS Imaging System 200 Series (Caliper Life Sciences, Hopkinton, MA) as previously described.
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Histology. Kidneys were fixed in formalin and embedded in paraffin. Sections were briefly stained with methylene blue in absolute alcohol for the detection of cystine crystals. Cystine crystals were quantified using ImageJ software (NIH, Bethesda, MD) on low magnification pictures of methylene blue stained sections covering most of the kidney section for each mouse. The threshold was adjusted to recognize specifically the cystine crystals, and pixels were quantified.
Cystine content measurement. Explanted tissues were ground in 750 μl of N-ethylmaleimide (Fluka Biochemika, Bushs, Switzerland) at 650 μg/ ml using the Precellys 24 homoginizer (Bertin Technologies, Montignyle-Bretonneux, France). For the in vitro assays, sorted cells were resuspended in 150 μl N-ethylmaleimide and sonicated for 10 seconds at an amplitude of 2 on ice. Proteins were precipitated using 15% 5-sulfosalicylic acid dihydrate (Fluka Biochemika, Buchs, Switzerland), resuspended in NaOH 0.1 N and measured using the Pierce BCA protein assay kit (Pierce, Rockford, IL). The cystine-containing supernatants were sent to the UCSD Biochemical Genetics laboratory for measurement by mass spectrometry as described previously.
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Blood and urine analysis. Serum was obtained by eye bleeds or cardiac puncture, and 24-hour urine collections were done in metabolic cages. Serum and urine phosphate levels, and serum creatinine and urea were estimated by using colorimetric assays according to the manufacturer recommendations (BioAssay Systems, Hayward, CA).
Blood and tissue DNA and RNA extraction. Tissue DNA and RNA were isolated from explanted tissues using the Qiagen AllPrep DNA/RNA Mini kit (Qiagen, Valencia, CA) and Qiagen QIAcube after homogenization in Precellys 24. Blood RNA was purified using the RNeasy Protect Animal Blood Kit (Qiagen). Blood DNA was purified with the DNeasy Tissue Kit (Qiagen) using the animal blood protocol.
Reverse transcription and qPCR. One microgram of blood RNA was reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). qPCR were performed using either 2 μl of cDNA or 200 ng of genomic DNA and 2x Universal TAQ man master mix (Applied Biosystems, Foster City, CA) on an Applied Biosystems 7900 HT (Applied Biosystems). Primers and probes were obtained from Applied Biosystems:
-CTNS-specific primers were designed in exon 9: Ctns oligo 1: CAAATACCCCAACGGAGTGAA, CTNS oligo 2: GCGTGCAGGCTGAA GAAGAC, and CTNS probe: CCCGTGAACAGCAAC.
-Lentivirus-specific primers were designed in the HIV-1 Psi region: pC CL oligo 1: ACTTGAAAGCGAAAGGGAAAC, pCCL oligo 2: CGCACCC ATCTCTCTCCTTCT, and pCCL probe: AGCTCTCTCGACGCAGGAC TCGGC.
